יחס חוב לטווח ארוך להון genenta.com (GNTA)

Genenta Science S.p.A. (GNTA) is developing unique gene therapy methods for brain cancer, protected by high R&D barriers. The share of long-term liabilities in equity, as presented on GURU.Markets, demonstrates financial stability, where 0.36 captures the current value of the indicator. The business relies on stable demand that is independent of macroeconomic conditions. Future drug approvals will grant the company monopolist status with absolute pricing power.

Genenta Science S.p.A. is developing gene therapies without commercial products, which makes the company dependent on research results. By analyzing long-term debt leverage on GURU.Markets, an investor can see the ratio of liabilities with a maturity of over one year to equity. This metric measures the extent of borrowing used to finance capital-intensive development. This allows for an assessment of the balance sheet structure's stability during periods of zero revenue. A high ratio signals risks, while a low ratio indicates conservative resource management.